Another explanation for differences between ours and published results (Demircioglu et al, 2020) is that FAK expression and/or signalling may be heterogeneous across patient tumours and within different CAF subsets in a same tumour, putatively explaining different biological consequences for FAK targeting. The gene discussed is PTK2; the disease is neoplasm.